This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment MT
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN CI
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M MT
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating MT
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating MT
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing MT
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer CI
Barclays Adjusts Price Target on SpringWorks to $47 From $41, Keeps Overweight Rating MT
Transcript : SpringWorks Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 07:30 AM
SpringWorks Therapeutics Closes $316.3 Million Common Stock Public Offering MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday MT
SpringWorks Therapeutics Prices $275 Million Share Offering MT
SpringWorks Therapeutics Launches $250 Million Public Offering of Shares; Stock Falls After Hours MT
Goldman Sachs Raises Price Target on SpringWorks Therapeutics to $52 From $47, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on SpringWorks Therapeutics to $73 From $64, Keeps Buy Rating MT
HC Wainwright Raises SpringWorks Therapeutics' Price Target to $64 From $52, Buy Rating Kept MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell MT
SpringWorks non-cancerous tumor drug to be priced at $29,000 per month in US RE
Transcript : SpringWorks Therapeutics, Inc. - Special Call
Chart SpringWorks Therapeutics, Inc.
More charts
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
42.75 USD
Average target price
67.78 USD
Spread / Average Target
+58.56%
Consensus
  1. Stock Market
  2. Equities
  3. SWTX Stock
  4. News SpringWorks Therapeutics, Inc.
  5. Goldman Sachs Raises Price Target on SpringWorks Therapeutics to $52 From $47, Maintains Buy Rating